

25 *Corresponding author:

26 E-mail: johken@med.tohoku.ac.jp (KJ)

27

28 **Abstract**

29 In immunoglobulin A nephropathy (IgAN), Cox regression analysis can select
30 independent prognostic variables for renal functional decline (RFD). However, the
31 correlation of the selected histological variables with clinical and/or treatment variables
32 is unknown, thereby making histology-based treatment decisions unreliable. We
33 prospectively followed 946 Japanese patients with IgAN for a median of 66 mo. and
34 applied structural equation modeling (SEM) to identify direct and indirect effects of
35 histological variables on RFD as a regression line of estimated glomerular filtration rate
36 (eGFR) via clinical variables including amount of proteinuria(UPE), eGFR, mean
37 arterial pressure(MAP) at biopsy, and treatment variables such as steroid therapy
38 with/without tonsillectomy(ST) and renin-angiotensin system blocker (RASB).
39 Multi-layered correlations between the variables and RFD were identified by
40 multivariate linear regression analysis and the model's goodness of fit was confirmed.
41 Only tubular atrophy/interstitial fibrosis (T) had an accelerative direct effect on RFD,
42 while endocapillary hypercellularity (E) and active crescent (C) had an attenuating
43 indirect effect via ST. S had an attenuating indirect effect via eGFR. M had accelerative
44 indirect effect for RFD via UPE. Moreover, M and C had accelerative indirect effect via
45 UPE, which can be controlled by ST. However, both T and S had additional indirect
46 accelerative effects via eGFR or MAP, which cannot be controlled by ST. SEM
47 identified a systemic path links between histological variables and RFD via dependent
48 clinical and/or treatment variables. These findings lead to clinically applicable novel

49 methodologies that can contribute to predict treatment outcomes using the Oxford
50 classifications.

51 **Introduction**

52 The international histological classification for IgA nephropathy (IgAN)
53 known as the Oxford classification was developed by defining and selecting relevant
54 pathological variables for renal functional decline (RFD). This classification utilizes
55 five pathological variables assessed individually: mesangial hypercellularity (M),
56 endocapillary hypercellularity (E), segmental glomerulosclerosis (S), tubular
57 atrophy/interstitial fibrosis (T), and cellular or fibrocellular (active) crescent (C) [1-3].
58 Almost all previous studies used traditional Cox regression analysis, which selects
59 independent prognostic variables to propose high-risk patients. However, the correlation
60 of the selected histological variables with clinical and/or treatment variables is
61 unknown, and this is important information when choosing therapy. As a consequence,
62 high-risk patients, irrespective of either active or chronic histological variables, equally
63 receive immunosuppressive treatment at the time of biopsy [4,5]. Due to a lack of
64 sufficient evidence for histology-based decision making, the Kidney Disease:
65 Improving Global Outcomes (KDIGO) guidelines recommend the choice of
66 immunosuppressant therapy be made, not based on histology, but mostly based on
67 clinical features indicating more than 1 g/d proteinuria around the time of biopsy and
68 during the two years after biopsy [6]. Therefore, risk stratification and treatment
69 decisions currently still rely on inaccurate categorization of these risk factors.

70 Recently, a new International Risk-Prediction Tool for IgAN has been
71 proposed as a more accurate tool to predict disease progression based on both
72 histological and clinical risk factors, including treatment choice [7-10]. This is a
73 personalized prediction model using an equation composed not only of clinical variables
74 including urine protein excretion (UPE), estimated glomerular filtration rate (eGFR),

75 and mean arterial pressure (MAP) at biopsy and treatment choice such as steroid
76 therapy (ST) and renin-angiotensin system blocker (RASB) but also the histological
77 variables MEST. This personalized equation predicts the probability of developing 50%
78 decrease in eGFR or end-stage renal disease in 5 years [8]. However, the formula is
79 composed of evenly evaluated histological, clinical, and treatment variables as a simple
80 summation in the exponential function [8,11]. Therefore, it is still not known how each
81 histological variable will respond to treatment choice after renal biopsy.

82 RFD is associated not only directly with histological, clinical, and/or treatment
83 variables, but also indirectly and unequally with clinical and/or treatment variables.
84 Structural equation modeling (SEM) is a method which can estimate these complex
85 interactions by adjusting for measurement errors in dependent variables using the error
86 term “ ϵ ,” reducing bias in correlation estimates [12,13].

87 In this prospective study, we therefore aimed to use SEM with multivariate
88 linear regression analysis to find structural paths of correlation between each
89 histological variable and slope as a regression line of eGFR (SLOPE) via clinical
90 variables and treatment choice. The appropriately fitting model, including direct and
91 indirect effects on RFD of Oxford classification variables via clinical and/or treatment
92 variables, can then be implemented clinically.

93

94 **Materials and methods**

95 **Objectives**

96 This was a prospective clinical study. Patients with IgAN were recruited and
97 their clinical data and renal biopsy materials collected at 44 kidney centers across Japan.
98 This clinical research project was produced by the ethical committee of The Research

99 Group on Progressive Renal Diseases organized by the Ministry of Health, Labour and
100 Welfare in Japan. The study protocol was in accordance with the standards of the ethics
101 committee at each center, and each patient consented to participate after being informed
102 of the purpose and procedure of the study.

103 Patients with IgAN registered between April 2005 and August 2015 in the
104 Japan IgA Nephropathy Prospective Cohort Study (JIGACS), which is a prospective
105 observational study conducted at facilities throughout Japan, were included in the study.
106 The protocol was approved by the Jikei University School of Medicine's Institutional
107 Review Board on Human Research, which acted as the main ethics committee for this
108 study (No. 16-174 [4402]). Of 1130 patients, we excluded those with more than one of
109 the following variables missing: MESTC score, baseline UPE, eGFR, or MAP, and
110 SLOPE measurements, or if they had no follow-up data after renal biopsy. Secondary
111 cases that showed mesangial IgA deposits, although with a predominant combined
112 disease such as diabetes mellitus, were excluded. After exclusions, 946 patients were
113 included in the study.

114 **Clinical data**

115 Normally distributed variables, as determined using the Shapiro–Wilk test,
116 non-parametric variables and categorical variables were expressed as mean \pm standard
117 deviation, as median and range, and as frequency and percentage, respectively. The data
118 were analyzed using SPSS version 24 (IBM Corp., USA).

119 Clinical variables, which were collected within 1 mo of biopsy and during
120 follow-up, were as follows. MAP was defined as diastolic pressure plus a third of the
121 pulse pressure. The eGFR was calculated as per the Japanese-based equation: eGFR
122 (ml/min/1.73 m²) = 194 \times serum creatinine (sCr)^{-1.094} \times age^{-0.287} (if female, \times 0.739)

123 [14]. In patients who were younger than 20 years, the eGFR was calculated
124 incorporating polynomial formulas for sCr and body length [15]. The Oxford study
125 excluded initial GFR <30 ml/min and initial proteinuria <0.5 mg/d, but no such
126 exclusion criteria were applied in this study. Treatments taken within a year after biopsy
127 were recognized as selected treatments: immunosuppressive treatment including ST
128 with/without tonsillectomy (reported as an intended treatment regardless of the type or
129 duration of therapy) or RASB indicating any exposure to angiotensin-converting
130 enzyme inhibitor, angiotensin receptor blockers, or both. If the patients had already
131 received RASB at the time of renal biopsy, this was also recorded as an initial
132 treatment. Weight, height, sCr, and amount of proteinuria (g/d) were also recorded.

133 **Outcomes**

134 In patients where more than two eGFR measurements were available, SLOPE
135 was calculated as a regression line and used as an outcome, as an indicator of RFD.

136 **Pathological data**

137 All cases were proven to be IgAN by biopsy. IgAN was defined by dominant
138 mesangial depositions of IgA and its presence in more than 10 glomeruli. Pathological
139 variables used in the present study included M0, M1, E0, E1, S0, S1, T0, T1, or T2, and
140 C0, C1, or C2, which were defined according to the Oxford classification [1-3]. Briefly,
141 M0 and M1 indicated the percentages of glomeruli with a mesangial hypercellularity of
142 0%–50% and <50%, respectively according to a simplification of the mesangial
143 hypercellularity score as shown in the Oxford study [1,2]. S0 or S1 and E0 or E1
144 indicated the absence or presence of S and E, respectively. T0, T1, and T2 indicated
145 interstitial fibrosis at 0%–25%, 26%–50%, and >50%, respectively. C0, C1, and C2
146 indicated the percentage of glomeruli with either a cellular or fibrocellular crescent at

147 0%, 1%–24%, and $\geq 25\%$, respectively. Renal biopsies were scored for pathological
148 variables according to the Oxford study by five renal pathologists (KJ, AH, AS, SH,
149 RK) blinded to the clinical data. When disagreement occurred between observers,
150 scoring was repeated by all five observers to reach a consensus. The agreement rate was
151 good or moderate in our previous study; the intraclass correlation coefficient of M, E, S,
152 T1/T2, and C1/C2 were 0.54, 0.57, 0.64, 0.72, and 0.57, respectively, among the five
153 pathologists [16].

154 **SEM**

155 SEM model building and estimation was done using STATA/SE version 15
156 (Light Stone, USA). A two-sided $P < 0.05$ was considered significant.

157 SEM included analysis of the direct paths between histological variables and
158 SLOPE and indirect paths between histological variables and SLOPE via clinical factors
159 and treatment choice, and linear regression analysis was used to find statistically
160 significant direct and indirect effects. Linear regression was used instead of Cox
161 regression to find indices of the model's statistical fit, as goodness of fit could not be
162 applied for the survival analysis model based on Cox multivariate analysis.

163 The candidate variables were selected according to a previous study by
164 Barbour et al. [8] We first created a hypothetical model consisting of all histological,
165 clinical, and treatment variables and SLOPE as a marker of RFD (Fig 1). Considering
166 normality, clinical variables were modified as follows: The baseline UPE0, baseline
167 square root eGFR0 (SReGFR0), and MAP at biopsy were centralized as each patient's
168 UPE0c, SReGFR0c, and MAPc, which was the value subtracted by an average of 946
169 patients in each category. Direct paths are indicated by arrows from each independent
170 histological variable (M, E, S, T, and C), clinical variable (centralized UPE [UPEc0],

171 centralized square root eGFR [SReGFR0c], or centralized MAP dichotomized with
172 negative MAPc as MAPc0 and positive MAPc as MAPc1 [MAPc01]), and treatment
173 variable (ST and RASB) after renal biopsy leading to SLOPE as an endpoint (Fig 1 a, b,
174 c). Indirect paths are indicated by arrows from each independent histological variable to
175 each mediating variable (clinical and treatment; Fig 1 d, e) and from each dependent
176 clinical variable to each dependent treatment variable (Fig 1 f). As MAP and eGFR can
177 affect the amount of proteinuria [6], the correlations between UPE0c and MAPc01 or
178 SReGFR0c were added as clinical variables. The correlations of a–f were estimated
179 using a multiple linear regression model. We reported standardized path coefficients
180 (SC), *P* values, and confidence intervals (CI). Additionally, error terms (ε_1 – ε_6), which
181 account for measurement error, were used in addition to latent clinical variables and
182 SLOPE.

183

184 **Fig 1. Hypothetical model incorporating all histological, clinical, and treatment**
185 **variables and the slope of change in estimated glomerular filtration rate (SLOPE),**
186 **as a marker of renal functional decline (RFD).**

187

188 Direct paths are indicated as arrows from each independent histological variable (M, E,
189 S, T, or C), clinical variable (UPEc0, SReGFR0c, and MAPc01), and treatment variable
190 (ST with/without tonsillectomy and renin-angiotensin system blocker [RASB]) after
191 renal biopsy leading to SLOPE (Fig 1 a,b,c). Indirect paths are indicated as each
192 histological variable pointing to each mediating variable (clinical and treatment, Fig 1 d,
193 e) and pointing to each dependent treatment variable from each dependent clinical
194 variable (Fig 1 f).

195

196 These calculations using the hypothetical model identified significant
197 correlations among histological, clinical, and treatment variables and SLOPE, allowing
198 a new model to be drawn. Only paths with correlations of $P < 0.1$ were drawn as arrows
199 in this revised model. To determine any elimination bias, it was checked whether link
200 paths with correlations of $P < 0.1$ were the same as those with correlations of $P < 0.05$.
201 An appropriately fitting model was proven using population error (root mean square
202 error of approximation [RMSEA] < 0.05 with 90% CI), baseline comparison
203 (comparative fit index [CFI] > 0.90), and size of residuals (standardized root mean
204 square residual [SRMSR] < 0.05) [17-19]. The sample size of 946 observations for the
205 present analysis consisting of 19 variables including M0, M1, E0, E1, S0, S1, T0, T1 or
206 T2, C0, C1 or C2, UPE0c, SReGFR0c, MAPc0, MAPc1, ST0, ST1, RASB0, RASB1,
207 and SLOPE was appropriate because an ideal sample size-to-parameters ratio would be
208 20:1, indicating that the minimum sample size should be 19×20 [20].

209

210 **Results**

211 **Clinical profile**

212 Clinical profiles of 946 Japanese with IgAN are shown in Table 1. Patients had
213 a median age of 37.1 years old (2.8–87.5 years old) and were followed up for a median
214 of 66 mo (1–174 mo). There was an equal distribution of males (49%) and females
215 (51%) indicating no gender-based skewing of the results. MAP at renal biopsy was
216 90.0 ± 13.7 mmHg and dichotomized and centralized MAPc1 was 45%. eGFR0 was
217 75.6 ± 28.9 ml/min and UPE0 was 1.1 ± 2.2 mg/dl. Body mass index (BMI) was 22.1 ± 3.8 .
218 The SLOPE was -0.10 ± 0.51 ml/min/1.73 m²/y.

219 **Table 1. Clinical, treatment, and histological profiles of the IgAN patients in this**
 220 **study.**

Clinical profile		Histological profile	
			n (%)
Cohort	946	M	
Male, n (%)	463 (49%)	M0	671 (71%)
Female, n (%)	483 (51%)	M1	275 (29%)
Age	37.1 (2.8–87.5)	E	
Ethnicity	Japanese	E0	611 (65%)
MAP at biopsy (mmHg)	90.0 ± 13.7	E1	335 (35%)
MAPc01, n (%)		S	
Yes	430 (45%)	S0	247 (26%)
No	516 (55%)	S1	699 (74%)
eGFR (ml/min/1.73 m²)	75.6 ± 28.9	T	
UPE0 (at biopsy)	1.1 ± 2.2	T0	739 (78%)
BMI	22.1 ± 3.8	T1	170 (18%)
eGFR slope (ml/min/1.73m²/y)	−0.10 ± 0.51	T2	37 (4%)
Period of follow-up (mo)	66 (1–174)	C	
		C0	580 (61%)
Treatment choice	n (%)	C1	357 (38%)
ST		C2	9 (1%)
Yes	605 (64%)		

No	341 (36%)		
RASB			
Yes	539 (57%)		
No	407 (43%)		

221 BMI: body mass index; eGFR: estimated glomerular filtration rate; MAP: mean arterial
222 pressure; MAPc01: centralized dichotomized MAP; RASB: renin-angiotensin system
223 blocker; ST: steroid therapy with/without tonsillectomy; UPE0: baseline urine protein
224 excretion. M0 and M1 indicated the percentages of glomeruli with a mesangial
225 hypercellularity of 0%–50% and <50%, respectively. S0 or S1 and E0 or E1 indicated
226 the absence or presence of S and E, respectively. T0, T1, and T2 indicated interstitial
227 fibrosis at 0%–25%, 26%–50%, and >50%, respectively. C0, C1, and C2 indicated the
228 percentage of glomeruli with either a cellular or fibrocellular crescent at 0%, 1%–24%,
229 and $\geq 25\%$, respectively.

230

231 **Treatment**

232 Table 1 shows an overview of treatment choices for the study participants. ST
233 was used to treat 64%, which included steroid pulse therapy in 20%, steroid pulse with
234 tonsillectomy in 38%, oral steroid therapy in 5%, and oral steroids with tonsillectomy in
235 1%. RAS blockade was used to treat 57%. A small proportion (5%) was treated only
236 with tonsillectomy, and 34% were not treated at all.

237 **Pathological profile**

238 Histological results from renal biopsy samples are shown in Table 1. The
239 proportion of the patients with M1, E1, S1, T1, T2, C1, and C2 was 29%, 35%, 74%,
240 18%, 4%, 38%, and 1%, respectively.

241 **SEM**

242 A hypothetical model was drawn as described in the Methods and tested with a
243 multivariate linear regression model using SEM (Fig 1). After removing non-significant
244 paths ($P > 0.1$), SEM was performed again to find an appropriately fitting model. The
245 significant paths were the same whether the significance threshold was set at $P < 0.05$ or
246 $P < 0.1$ as shown in Fig 2. Therefore, no elimination bias was apparent. As indices of the
247 models' statistical fit, RMSEA, CFI, and SRMSR were 0.05 as same as 0.05, 0.93 as
248 more than 0.90, and 0.03 as less than 0.05, respectively. Therefore, these results indicate
249 that the model was an appropriate fit according to a likelihood estimation of appropriate
250 fit as shown in the Methods [17,18].

251

252 **Fig 2. SEM was performed to find an appropriate fitting model after removing**
253 **non-significant paths ($P > 0.05$).**

254

255 Statistically significant paths between histological variables, clinical variables, or
256 treatment variables and SLOPE are shown as arrows with standardized coefficients
257 marked. T, besides ST, UPE0c, and SReGFR0c, showed direct correlations with
258 SLOPE ($P < 0.05$) (blue arrows). All histological variables showed indirect effects on
259 SLOPE via clinical variables or ST (red arrows).

260 Analyzing indirect contributors to SLOPE, ST, which correlated with S, E, C, UPE0c,
261 SReGFR0c, and MAPc01, was correlated with SLOPE. RASB, which correlated with
262 UPE0c, SReGFR0c, and MAPc01, was not correlated with SLOPE. The error terms ϵ_1 –
263 ϵ_6 of each of MAPc01, SReGFR0c, UPEc0, ST, RASB, and SLOPE were 0.93, 0.68,
264 0.89, 0.88, 0.83, and 0.95, respectively.

265

266 In the SEM analysis, statistically significant direct correlations with SLOPE (*P*
 267 <0.05) were independent accelerative histological variable T, independent accelerative
 268 clinical variables UPE0c and SReGFR0c, and independent attenuating treatment
 269 variable ST. As well as the direct correlations with SLOPE, correlations between
 270 clinical and histological variables and between treatment and histological variables or
 271 clinical variables were calculated and indicated indirect correlations with SLOPE (Fig 2
 272 and Table 2). UPE0c positively correlated with M and C and negatively correlated with
 273 SReGFR0c. MAPc01 positively correlated with S and T. SReGFR0c negatively
 274 correlated with S and T. ST negatively correlated with MAP01c and positively
 275 correlated with UPE0c, SReGFR0c, S, E, and C. RASB, although correlated with
 276 UPE0c, MAPc01, and SReGFR0c, was not an independent variable for SLOPE.

277

278 **Table 2. Direct and indirect correlations between histological variables and change**
 279 **in estimated glomerular filtration rate (SLOPE) via clinical variables and**
 280 **treatment variables.**

	SC	SE	z	P>z	[95% Confidence Interval]	
SLOPE						
UPE0c	-0.073	0.033	-2.200	0.028	-0.138	-0.008
SReGFR0c	-0.224	0.039	-5.800	<0.001	-0.299	-0.148
ST	0.127	0.032	3.99	<0.001	0.065	0.19
T	-0.095	0.038	-2.500	0.013	-0.170	-0.020
_cons	-0.318	0.056	-5.630	<0.001	-0.429	-0.207
UPE0c						

SReGFR0c	-0.205	0.031	-6.660	<0.001	-0.266	-0.145
M	0.194	0.031	6.26	<0.001	0.133	0.254
C	0.102	0.031	3.31	0.001	0.042	0.162
_cons	-0.205	0.042	-4.870	<0.001	-0.287	-0.122
MAPc01						
S	0.091	0.032	2.84	0.004	0.028	0.152
T	0.237	0.03	7.79	<0.001	0.177	0.297
_cons	0.637	0.066	9.61	<0.001	0.507	0.766
SReGFR0c						
S	-0.095	0.027	-3.52	<0.001	-0.148	-0.042
T	-0.545	0.021	-25.740	<0.001	-0.587	-0.504
_cons	0.448	0.051	8.79	<0.001	0.349	0.548
ST						
UPE0c	0.108	0.032	3.41	0.001	0.046	0.17
MAPc01	-0.069	0.033	-2.100	0.036	-0.133	-0.004
SReGFR0c	0.109	0.034	3.24	0.001	0.043	0.175
S	0.127	0.032	3.97	<0.001	0.064	0.19
E	0.114	0.033	3.41	0.001	0.048	0.18
C	0.180	0.034	5.24	<0.001	0.112	0.247
_cons	0.956	0.076	12.53	<0.001	0.807	1.106
RASB						
UPE0c	0.088	0.03	2.88	0.004	0.028	0.147
MAPc01	0.207	0.031	6.61	0	0.146	0.269

SReGFR0c	-0.300	0.031	-9.550	0	-0.361	-0.238
_cons	0.976	0.049	19.87	0	0.88	1.072

281 SC: standardized coefficient; SE: standard error; T: tubular atrophy/interstitial fibrosis;
 282 M: mesangial hypercellularity; C: active crescent; S: segmental glomerulosclerosis; E:
 283 endocapillary hypercellularity; ST: steroid therapy including tonsillectomy; RASB:
 284 renin-angiotensin system blocker; UPE0c: centralized base line urine protein excretion;
 285 SReGFR0c: centralized square root baseline eGFR; MAPc01: centralized dichotomized
 286 baseline mean arterial pressure; cons: constant

287

288 As shown in Table 3, direct and/or indirect effects of histological variables on
 289 SLOPE were calculated as total coefficients by combining the direct and indirect
 290 coefficients for each histological variable (Table 3). The total coefficients were the
 291 sums of the direct and indirect coefficients, where each indirect coefficients of M, E, S,
 292 T, or C in Table 3 was the integration of each coefficient of the clinical and treatment
 293 variables in Table 2 according to the paths shown in Fig 2, which stood between
 294 histological variables and SLOPE (Fig 2). T showed an total accelerative effect
 295 composed of the direct accelerative coefficient and the indirect accelerative coefficients
 296 as via SReGFR0c and ST and via MAPc01 and ST. E showed an attenuating indirect
 297 effect via ST. C showed an attenuating indirect effect composed of an attenuating
 298 indirect effect via ST and attenuating indirect effect via UPE0c and ST. S showed an
 299 attenuating indirect effect via SReGFR0c and additionally an accelerative indirect effect
 300 via SReGFR0c and ST, as well as via MAPc01 and ST. M showed an accelerative effect
 301 composed of accelerative indirect effect via UPE0c and an attenuating indirect effect via
 302 UPE0c and ST (Table 3). In summary, only T showed an accelerative direct effect on

303 RFD, whereas E and C were not independent variables for RFD, correlated significantly
 304 with ST, and showed attenuating effects on RFD via ST. S showed attenuating effects
 305 on RFD via SReGFR0c. Both C and M had additional accelerative effects via UPE0c,
 306 which can be controlled by ST, thus changing the accelerative effect to attenuating
 307 effect. On the other hand, both T and S had additional indirect accelerative effects on
 308 RFD via SReGFR0c or via MAPc01, which could not be controlled by ST, thus
 309 continuing to exhibit the accelerative effect. The error terms ϵ_1 – ϵ_6 of each MAPc01,
 310 SReGFR0c, UPEc0, ST, RASB, and SLOPE were 0.93, 0.68, 0.89, 0.88, 0.83, and 0.95,
 311 respectively (Fig 2).

312

313 **Table 3. Direct and indirect effects of Oxford histological variables on change in**
 314 **estimated glomerular filtration rate (SLOPE).**

Histological variable	Direct coefficient	Indirect		Total coefficient
		coefficient	via	
M		-0.014	UPE0c	-0.011
M		0.003	UPE0c, ST	
E		0.014	ST	0.014
S		0.021	SReGFR0c	0.019
S		-0.001	SReGFR0c, ST	
S		-0.001	MAPc01, ST	
T	-0.095			-0.105
T		-0.008	SReGFR0c, ST	
T		-0.002	MAPc01, ST	
C		0.023	ST	0.024

C		0.001	UPE0c, ST	
---	--	-------	-----------	--

315 M: mesangial hypercellularity; E: endocapillary hypercellularity; S: segmental
316 glomerulosclerosis; T: tubular atrophy/interstitial fibrosis; C: active crescent;
317 SReGFR0c: centralized square root baseline eGFR; MAPc01: centralized dichotomized
318 baseline mean arterial pressure; UPE0c: centralized baseline urine protein excretion;
319 ST: steroid therapy including tonsillectomy

320

321 **Discussion**

322 In this prospective multicenter study involving 946 Japanese IgAN patients, we
323 applied SEM to evaluate structural correlations associated with the change in eGFR as
324 RFD (SLOPE). Consequently, this analysis showed systemic path links between
325 SLOPE and histological variables via clinical and/or treatment variables.

326 We identified the contributors to SLOPE as T (T1 or T2, independent
327 accelerative histological variable), SReGFR0c and UPE0c (independent accelerative
328 clinical variables), and ST (independent attenuating treatment variable). RASB was not
329 an independent variable for SLOPE. Further, the selected contributors as well as the
330 independent variables for SLOPE were connected via dependent histological, clinical,
331 and/or treatment variables. Therefore, we investigated the statistically significant
332 structural correlations among the histological, clinical, and treatment variables and
333 SLOPE.

334 Using the coefficients of the direct and indirect correlations, we calculated the
335 total effect of each histological variable on SLOPE (Table 3). T was the only
336 histological variable with a direct (accelerative) effect on SLOPE. It had additional
337 indirect effects (accelerative) via SReGFR0c or MAPc01, which could not be controlled

338 by ST, thus maintaining the accelerative effect. Both E and C attenuated SLOPE via ST.
339 M showed an overall accelerative effect on SLOPE, thereby incorporating an
340 accelerative effect via UPE0c. Further, both M and C had additional accelerative effects
341 on SLOPE via UPE0c, which was controlled by ST, thereby transforming the
342 accelerative effect to attenuating effect. S had an attenuating indirect effect via eGFR.
343 Moreover, both T and S had indirect accelerative effects via eGFR0c or MAP, which
344 could not be controlled by ST, thus continuing with the accelerating effect. If S0
345 developed to S1, SReGFR0c decreased (Table 2). This negative correlation meant that if
346 eGFR at biopsy was high, SLOPE declined strongly, while if it was low, there was a
347 weaker decline. This is also true in normal kidneys [21].

348 The above findings suggest that ST was chosen for patients with E1 and C1 or
349 C2 but not with T1 or T2 and that it effectively attenuated decline in eGFR. This is in
350 partial agreement with another Japanese study, which found that patients with E1, S1, or
351 C1 treated with ST had significantly better prognosis than the non-treatment group [22].
352 Similarly, in two other studies, the presence of E was strongly associated with
353 subsequent ST, and there was a higher rate of decline in renal function in patients who
354 were not treated with immunosuppressants [1] or corticosteroids [23]. Our study also
355 showed that C and M had additional accelerating effects via UPE0c on SLOPE, which
356 were controlled and thus led to the change from accelerative to attenuating effect by ST.
357 Therefore, ST can be considered to be effective for the patients with C and M by
358 diminishing the accelerative effect of UPE0c. Other studies have shown that patients
359 had an increased risk of disease progression with extremely increasing C, even with
360 immunosuppression [5,24,25]. T and S had additional accelerative effects via SReGFR0
361 or MAPc01, which could not be controlled by ST. This is consistent with the previous

362 findings, which reported that S (as well as M and T) had predictive prognostic value for
363 RFD [1,5,23]. However, the prognostic role of S1 for RFD can be small, when early ST
364 prevented a progression from active crescent as C1/C2 to S. M appears to be a sensitive
365 histological variable, as it can also be a risk factor for RFD via acceleration of
366 proteinuria, when proteinuria cannot be controlled by ST [5,26,27]. However, the
367 original Oxford study selected S1 and T1/T2 but not M1 for RFD in a multivariate
368 linear regression model adjusted for initial eGFR, MAP, and UPE0 [1,28]. The
369 VALIGA study suggested also M1 was a steroid-responsive variable [26,29,30]. These
370 conflicting results illustrate the benefit of analyzing both the direct and indirect effects.

371 We were able to stratify the Oxford histological classifications from the
372 viewpoint of treatment response in predicting future outcomes. Several validation
373 studies of the Oxford classification using Cox analysis showed merely different
374 independent histological, clinical, and treatment variables without suggesting their
375 concrete clinical use, which may depend on differences in the cohorts [4,5,31,32]. SEM
376 can clarify these differences by analyzing the correlations between Oxford histological
377 variables and RFD via clinical and treatment variables.

378 In conclusion, SEM identified a systemic path links between histological
379 variables and RFD via dependent clinical and/or treatment variables. To the best of our
380 knowledge, there has been no such systematic research previously to propose the
381 correlation among histological, clinical, and treatment variables in depth. These findings
382 lead to clinically applicable novel methodologies that can contribute to predict treatment
383 outcomes using the Oxford classifications and improve care for IgAN patients using
384 personalized medicine.

386 **Acknowledgments**

387 We thank the study participants for their kind cooperation. The authors would like to
388 thank Enago (www.enago.jp) for the English Language review.

389

References

- 390 1. Working Group of the International Ig ANN, Cattran DC, Coppo R, Cook HT,
391 Feehally J, Roberts IS, et al. The Oxford classification of IgA nephropathy:
392 rationale, clinicopathological correlations, and classification. *Kidney Int.*
393 2009;76: 534-45.
- 394 2. Working Group of the International Ig ANN, Roberts IS, Cook HT, Troyanov S,
395 Alpers CE, Amore A, et al. The Oxford classification of IgA nephropathy:
396 pathology definitions, correlations, and reproducibility. *Kidney Int.* 2009;76:
397 546-56.
- 398 3. Haas M, Verhave JC, Liu ZH, Alpers CE, Barratt J, Becker JU, et al. A
399 multicenter study of the predictive value of crescents in iga nephropathy. *J Am*
400 *Soc Nephrol.* 2017;28: 691-701.
- 401 4. Haas M, Rastaldi MP, Fervenza FC. Histologic classification of glomerular
402 diseases: clinicopathologic correlations, limitations exposed by validation
403 studies, and suggestions for modification. *Kidney Int.* 2014;85: 779-93.
- 404 5. Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford
405 Classification of IgA nephropathy 2016: an update from the IgA Nephropathy
406 Classification Working Group. *Kidney Int.* 2017;91: 1014-21.
- 407 6. Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, et al.
408 Management and treatment of glomerular diseases (part 1): conclusions from a

- 409 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies
410 Conference. *Kidney Int.* 2019;95: 268-80.
- 411 7. Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J,
412 et al. The MEST score provides earlier risk prediction in IgA nephropathy.
413 *Kidney Int.* 2016;89: 167-75.
- 414 8. Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, et al.
415 Evaluating a new international risk-prediction tool in IgA nephropathy. *JAMA*
416 *Intern Med.* 2019;179: 942-52.
- 417 9. Barbour SJ, Canney M, Coppo R, Zhang H, Liu ZH, Suzuki Y, et al. Improving
418 treatment decisions using personalized risk assessment from the International
419 IgA Nephropathy Prediction Tool. *Kidney Int.* 2020;98: 1009-19.
- 420 10. Barbour SJ, Feehally J. Predicting the future in immunoglobulin A nephropathy:
421 a new international risk prediction tool. *Nephrol Dial Transplant.* 2020;35:
422 379-82.
- 423 11. Zhang Y, Guo L, Wang Z, Wang J, Er L, Barbour SJ, et al. External validation
424 of international risk-prediction models of IgA nephropathy in an
425 Asian-Caucasian cohort. *Kidney Int Rep.* 2020;5: 1753-63.
- 426 12. Gardiner L, Akintola A, Chen G, Catania JM, Vaidya V, Burghardt RC, et al.
427 Structural equation modeling highlights the potential of Kim-1 as a biomarker
428 for chronic kidney disease. *Am J Nephrol.* 2012;35: 152-63.
- 429 13. Chen HW, Chen YC, Yang FM, Catania JM, Vaidya V, Burghardt RC, et al.
430 Mediators of the effects of gender on uric acid nephrolithiasis: a novel
431 application of structural equation modeling. *Sci Rep.* 2018;8: 6077.

- 432 14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised
433 equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis.*
434 2009;53: 982-92.
- 435 15. Uemura O, Nagai T, Ishikura K, Ito S, Hataya H, Gotoh Y, et al.
436 Creatinine-based equation to estimate the glomerular filtration rate in Japanese
437 children and adolescents with chronic kidney disease. *Clin Exp Nephrol.*
438 2014;18: 626-33.
- 439 16. Hisano S, Joh K, Katafuchi R, Shimizu A, Hashiguchi N, Kawamura T, et al.
440 Reproducibility for pathological prognostic parameters of the Oxford
441 classification of IgA nephropathy: a Japanese cohort study of the Ministry of
442 Health, Labor and Welfare. *Clin Exp Nephrol.* 2017;21: 92-6.
- 443 17. Rakotoasimbola E, Blili S. Measures of fit impacts: Application to the causal
444 model of consumer involvement. *Int J Mark Res.* 2018;61: 77-92.
- 445 18. Kline RB. Principles and practice of structural equation modeling. 4th ed. New
446 York: Guilford Press; 2016.
- 447 19. Tripathy JP, Thakur JS, Jeet G, Jain S. Structural equation modeling to identify
448 the risk factors of diabetes in the adult population of North India. *Trop Med*
449 *Health.* 2018;46: 23.
- 450 20. Fan X, Thompson B, Wang L. Effects of sample size, estimation methods, and
451 model specification on structural equation modeling fit indexes. *Struct Equ*
452 *Modeling.* 2009;6: 56-83.
- 453 21. Baba M, Shimbo T, Horio M, Ando M, Yasuda Y, Komatsu Y, et al.
454 Longitudinal study of the decline in renal function in healthy subjects. *PLoS*
455 *One.* 2015;10: e0129036.

- 456 22. Moriyama T, Karasawa K, Miyabe Y, Akiyama K, Ogura S, Takabe T, et al.
457 Validation of the revised Oxford classification for IgA nephropathy considering
458 treatment with corticosteroids/immunosuppressors. *Sci Rep.* 2020;10: 11151.
- 459 23. Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, et al.
460 Validation of the Oxford classification of IgA nephropathy. *Kidney Int.*
461 2011;80: 310-7.
- 462 24. Lv J, Shi S, Xu D, Zhang H, Troyanov S, Cattran DC, et al. Evaluation of the
463 Oxford Classification of IgA nephropathy: a systematic review and
464 meta-analysis. *Am J Kidney Dis.* 2013;62: 891-9.
- 465 25. Katafuchi R, Ninomiya T, Nagata M, Mitsuiki K, Hirakata H. Validation study
466 of oxford classification of IgA nephropathy: the significance of extracapillary
467 proliferation. *Clin J Am Soc Nephrol.* 2011;6: 2806-13.
- 468 26. Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al.
469 Validation of the Oxford classification of IgA nephropathy in cohorts with
470 different presentations and treatments. *Kidney Int.* 2014;86: 828-36.
- 471 27. Yang P CX, Zeng L, Hao H, Xu G. The response of the Oxford classification to
472 steroid in IgA nephropathy: a systematic review and meta-analysis. *Oncotarget.*
473 2017;8: 59748-56.
- 474 28. Yoon CY, Chang TI, Kang EW, Lim BJ, Kie JH, Kee YK, et al. Clinical
475 usefulness of the Oxford classification in determining immunosuppressive
476 treatment in IgA nephropathy. *Ann Med.* 2017;49: 217-29.
- 477 29. Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, et al. Is
478 there long-term value of pathology scoring in immunoglobulin A nephropathy?

- 479 A validation study of the Oxford Classification for IgA Nephropathy (VALIGA)
480 update. *Nephrol Dial Transplant*. 2020;35: 1002-9.
- 481 30. Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, et al.
482 Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA
483 study. *J Am Soc Nephrol*. 2015;26: 2248-58.
- 484 31. Moriyama T. Clinical and histological features and therapeutic strategies for IgA
485 nephropathy. *Clin Exp Nephrol*. 2019;23: 1089-99.
- 486 32. Joh K, McNamara K. Differences of histological classification between the
487 Japanese Histological Grade Classification and the Oxford Classification. In:
488 Tomino, editor. *Pathogenesis and treatment in IgA nephropathy*. Springer:
489 Tokyo, Japan; 2016. p 69-87.




Fig.2




Fig.1